Thermo Fisher Scientific (TMO) Cost of Revenue (2009 - 2026)

Thermo Fisher Scientific has reported Cost of Revenue for 18 years, with the latest figure at $3.6 billion in Q2 2026.

• Cost of Revenue for Q2 2026 came in at $3.6 billion, up 12.69% year-over-year; the trailing twelve-month figure through Jun 2026 was $14.0 billion (up 9.65% YoY), and the FY2025 annual result was $13.4 billion, up 5.93% from the prior year.
• Cost of Revenue grew to $3.6 billion in Q2 2026, from $3.3 billion in the prior quarter.
• Over five years, Cost of Revenue peaked at $3.7 billion in Q4 2025 and troughed at $3.1 billion in Q2 2024.
• A 5-year average of $3.4 billion and a median of $3.3 billion in 2025 frame the typical range for Cost of Revenue.
• The widest annual swing landed in 2022, when Cost of Revenue surged 10487.88%; it then fell 9.32% in 2023.
• A 5-year view of Cost of Revenue shows it stood at $3.7 billion in 2022, then decreased by 9.32% to $3.3 billion in 2023, then decreased by 2.99% to $3.2 billion in 2024, then advanced by 14.91% to $3.7 billion in 2025, then declined by 1.93% to $3.6 billion in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $3.6 billion in Q2 2026, $3.3 billion in Q1 2026, and $3.7 billion in Q4 2025.